Al-Jazeerah: Cross-Cultural Understanding

News, May 2020


Al-Jazeerah History


Mission & Name  

Conflict Terminology  


Gaza Holocaust  

Gulf War  




News Photos  

Opinion Editorials

US Foreign Policy (Dr. El-Najjar's Articles)




Editorial Note: The following news reports are summaries from original sources. They may also include corrections of Arabic names and political terminology. Comments are in parentheses.

Share the link of this article with your facebook friends


287,621 Deaths, 4,273,104 Corona Virus Infections, Mostly in the US, UK, Italy, Spain, France, Brazil, Belgium, Germany, and the Netherlands

May 12, 2020 

Dr. Anthony Fauci speaks during a White House coronavirus task force briefing, on April 17, 2020  


World 4,273,104 infection cases, and 287,621 deaths.

As of May 012, 2020, 10:52 GMT 

A list of countries with the highest and lowest Coronavirus (Covid-19) deaths:

USA 1,385,850 cases, 81,795 deaths.

UK 223,060 cases, 32,065 deaths.

Italy 219,814 cases, 30,739 deaths.

Spain 268,143 cases, 26,744 deaths.

France 177,423 cases, 26,643 deaths.

Brazil 169,594 cases, 11,653 deaths.

Belgium 53,779 cases, 8,761 deaths.

Germany 172,576 cases, 7,661 deaths.

Netherlands 42,788 cases, 5,456 deaths.

Chile 30,063 cases, 323 deaths.

Saudi Arabia 41,014 cases, 255 deaths.

South Africa 10,652 cases, 206 deaths.

Nigeria 4,641 cases, 150 deaths.

Belarus 23,906 cases, 135 deaths.

Kuwait 9,286 cases, 65 deaths.

Ghana 4,700 cases, 22 deaths. 


WHO Director-General's opening remarks at the media briefing on COVID-19

 11 May 2020, «Šŕ—»Ū…, 中文

Good morning, good afternoon and good evening.

There have now been more than four million cases of COVID-19 across the world.

Over the past week several countries have started lifting stay at home orders and other restrictions in a phased way.

Countries put these stringent measures in place, sometimes called lockdowns, in response to intense transmission.

Many have used the time to ramp up their ability to test, trace, isolate and care for patients, which is the best way to track the virus, slow the spread and take pressure off the health systems.

The good news is that there has been a great deal of success in slowing the virus and ultimately saving lives. 

However, such strong measures have come at a cost and we recognize the serious socio-economic impact of the lockdowns, which have had a detrimental effect on many peopleís lives.

Therefore, to protect lives and livelihoods, a slow, steady, lifting of lockdowns is key to both stimulating economies, while also keeping a vigilant eye on the virus so that control measures can be quickly implemented if an upswing in cases is identified.
I have previously outlined the six criteria countries need to consider before lifting stay at home orders and other restrictions.

Over the weekend, further guidance was published that outlines the three key questions countries should ask prior to the lifting of lockdowns:

First, is the epidemic under control?

Second, is the healthcare system able to cope with a resurgence of cases that may arise after relaxing certain measures?

Third, is the public health surveillance system able to detect and manage the cases and their contacts, and identify a resurgence of cases?

These three questions can help determine whether a lockdown can be released slowly or not.

However, even with three positive answers, releasing lockdowns is both complex and difficult.

Over the weekend we saw signs of the challenges that may lie ahead.

In the Republic of Korea, bars and clubs were shut as a confirmed case led to many contacts being traced.  

In Wuhan, China, the first cluster of cases since their lockdown was lifted was identified.

Germany has also reported an increase in cases since an easing of restrictions.
Fortunately, all three countries have systems in place to detect and respond to a resurgence in cases.

Early serological studies reflect that a relatively low percentage of the population has antibodies to COVID-19, which means most of the population is still susceptible to the virus.

WHO is working closely with governments to ensure that key public health measures remain in place to deal with the challenge of lifting lockdowns.

Until there is a vaccine, the comprehensive package of measures is our most effective set of tools to tackle the virus.  

In this vein, new guidance was released over the weekend regarding both school and work places reopening.

On children going back to school, decision makers should reflect on a number of key factors when deciding on whether and how to reopen schools:

First, a clear understanding about current COVID-19 transmission and severity of the virus in children is needed.

Second, the epidemiology of COVID-19 where the school is geographically located needs to be considered.

Third, the ability to maintain COVID-19 prevention and control measures within the school setting.

When reflecting on the decision to reopen schools, the local government should assess the capacity of the schools to maintain infection, prevention and control measures.

Last week, I also spoke to the International Labour Organisation (ILO) and the International Organisation of Employers (IOE) about the reopening of work places and how to do this safely.

Over the weekend, WHO issued detailed new workplace guidelines, which recommend all places of work carry out a risk assessment for workers potential exposure to COVID-19. This includes the implementation of measures to prevent the spread of the virus.

Workplaces should develop action plans for prevention and mitigation of COVID-19 as part of their overall business plan.

The plan should also include measures for protecting health, safety, and security in re-opening, closing, and modifying workplaces.

Today saw the release of new modeling on HIV by the World Health Organization and UNAIDS.

It highlights the importance of taking immediate steps to minimise interruptions in health services and supplies of antiretroviral drugs during the COVID-19 pandemic.

The groupís worst case scenario, a 6-month disruption of antiretroviral therapy, suggested that there could be 500,000 extra deaths from AIDS-related illnesses, including from tuberculosis, in sub-Saharan Africa over the next year.

This could effectively set the clock back by more than a decade to 2008, when more than 950,000 AIDS deaths were observed in the region.

This is an avoidable worst-case scenario and not a prediction. This model acts as a wake-up call to identify ways to sustain all vital health services.

Despite attention being focused on the COVID-19 pandemic, we must still ensure that global supplies of tests and treatments for both HIV and TB reach the countries and communities that need them most. We should save people from COVID and HIV and other life threatening diseases.

Even relatively short-term interruptions to treatment pose a significant threat to a personís health and potential to transmit HIV.


COVID-19 has exposed the uneven distribution of life-saving medical equipment across the world.

Tomorrow, the Tech Access Partnership will be launched to increase local production of essential health technologies Ė like masks and ventilators - in developing countries.  

This new partnership is another great example of solidarity that builds on the solidarity flights, solidarity trials and Access to COVID-19 Tools Accelerator, which all aim to ensure the latest health innovations are reaching those communities that need them most.

Only together can we get through this pandemic. In national unity and global solidarity.

I repeat, only together can we get through this pandemic. In national unity and global solidarity.

I thank you.


Anthony Fauci Says More than One Coronavirus Vaccine Needed to End Pandemic

By Aila Slisco

Newsweek, May 12, 2020

Dr. Anthony Fauci and other leading health experts have suggested that more than one vaccine may be needed to effectively combat the COVID-19 pandemic due to production limitations and overwhelming demand.

Fauci co-authored a paper published in the journal Science on Monday, suggesting that demand for an effective coronavirus vaccine is likely to far exceed supplies of any single vaccine. The White House coronavirus task force member wrote the paper alongside Fred Hutchison Cancer Research Center's Dr. Larry Corey and colleagues at the National Institutes of Health (NIH), including NIH Director Dr. Francis Collins and vaccine expert Dr. John Mascola.

"There is an unprecedented need to manufacture and distribute enough safe and effective vaccine to immunize an extraordinarily large number of individuals," the paper states. "No single vaccine or vaccine platform alone is likely to meet the global need, and so a strategic approach to the multi-pronged endeavor is absolutely critical."

While several vaccines for the virus are currently in development, scientists have cautioned that developing even a single effective vaccine presents a significant challenge. The delay between developing vaccines and making them available to the public is often years, although officials hope that a coronavirus vaccine will be available record time.

A massive amount of funding has been provided for coronavirus vaccines and development is being aided by programs like NIH's "ACTIV" initiative, a partnership between government agencies and pharmaceutical companies aiming to accelerate the development of vaccines and therapies for COVID-19. Still, scientists believe additional funding may be needed to be successful on a global scale.

"We want to see multiple successful vaccines and vaccine platforms meet the global need of immunizing billions of adults, children and restoring economic and health to the world," Corey said in a press release.

The paper notes that there have been relatively few mutations of the spike-shaped protein that the virus uses to attach to cells, providing "cautious optimism" that any vaccines being developed now will still be effective when they are ready to be given to populations.

Collins expects that multiple candidate vaccines will be successfully developed, potentially offering distinct benefits that could prove effective for different people.

"My expectation is, and I am a bit of an optimist, that we don't find out that there's only one of these vaccines that works, but rather two or three of them come through the trials looking as though they're safe and effective," Collins told Bloomberg on Monday. "They'll have somewhat different characteristics of where they work best, so we might need to do some matching then of which vaccine goes to which particular population."

However, any effective vaccines that are developed will require "the vaccine-manufacturing capacity of the entire world" to meet demand posed by the pandemic, the paper says.

Newsweek reached out to Fauci for additional comment. This article will be updated with any response.


Share the link of this article with your facebook friends

Fair Use Notice

This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.




Opinions expressed in various sections are the sole responsibility of their authors and they may not represent Al-Jazeerah & &